![Sana Biotechnology, Inc.](https://parsers.vc/logo/4afb5ea0-9d51-4e30-80ce-f7dae565e1ba-4.jpg)
Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy.
Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders.
Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.
Location: United States, Washington, Seattle
Employees: 201-500
Total raised: $2.79B
Valuation: $6.5B
Founded date: 2018
Investors 9
Funding Rounds 4
Date | Series | Amount | Investors |
04.02.2021 | IPO | $587.5M | - |
23.10.2020 | - | $700M | - |
25.06.2020 | - | $700M | - |
07.01.2019 | - | $800M | - |
Mentions in press and media 40
Date | Title | Description | Source |
18.03.2024 | Anthropic-backer Menlo Ventures is preparing for a 'gold rus... | Startups Anthropic-backer Menlo Ventures is preparing for a 'gold rush' of AI infrastructure startup... | businessin... |
10.10.2023 | Sana Biotechnology Announces Increased Focus on Hypoimmune-R... | - | globenewsw... |
11.04.2023 | Tech Moves: Adaptive Biotechnologies COO departing; Sana add... | Mark Adams. (Adaptive Photo) — Mark Adams is stepping down as chief operating officer of Adaptive Bi... | geekwire.c... |
10.04.2023 | Tech Moves: Halo leader departing; Remitly adds board direct... | Phyllis Campbell (left) and Ryno Blignaut. — Seattle-based fintech company Remitly added two new boa... | geekwire.c... |
11.01.2022 | Sana Biotechnology, IASO Biotherapeutics, and Innovent Biolo... | SEATTLE, SAN FRANCISCO, SAN JOSE, Calif., NANJING, China, SUZHOU, China and SHANGHAI, Jan. 11, 2022 ... | en.prnasia... |
11.01.2022 | Sana Biotechnology, IASO Biotherapeutics, and Innovent Biolo... | SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China and SHANGHAI, Ja... | en.prnasia... |
19.10.2021 | Sage, Biogen head to FDA with $3.1B depression drug; Sana... | Weeks after announcing they would drop a pair of studies deemed unnecessary to file the depr... | endpts.com... |
15.07.2021 | Catalent lands 2 new partnerships, including for gliobl... | It’s been a quiet few weeks for one of the busiest CDMOs out there, but Catalent broke its lull w... | endpts.com... |
15.07.2021 | Eli Lilly partners with Alzheimer's center for PhIII stu... | As Eli Lilly preps to submit its Alzheimer’s candidate donanemab to the FDA following Biogen... | endpts.com... |
15.07.2021 | A Chinese I/O biotech looking to turn around an old Novar... | Close to a year after pulling in its last private fundraise, Chinese immuno-oncology biotech ... | endpts.com... |
Show more